Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues

Bioconjugate Chemistry

Volumn 26, Issue 11, 2015, Pages 2243-2248

  Li, Xiuling ^a   Patterson, James T ^b   Sarkar, Mohosin ^a   Pedzisa, Lee ^a   Kodadek, Thomas ^a   Roush, William R ^a   Rader, Christoph ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS;

'CURRENT; ACQUIRED RESISTANCE; ANTIBODY CONJUGATION; ANTIBODY-DRUG CONJUGATES; SELENOCYSTEINE; SITE-SPECIFIC; SPECIFIC CONJUGATIONS; THERAPEUTIC INDEX;

ANTIBODIES;

ANTIBODY; ANTIBODY CONJUGATE; BIOTIN; CYSTEINE; ELECTROPHILE; GLUTATHIONE; HORSERADISH PEROXIDASE; IODOACETAMIDE; MONOCLONAL ANTIBODY; SELENOCYSTEINE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ANTIBODY ENGINEERING; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CONJUGATION; CONTROLLED STUDY; ELECTROPHILICITY; FLOW CYTOMETRY; HUMAN; MASS SPECTROMETRY; PHARMACODYNAMICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURFACE PLASMON RESONANCE; CHEMISTRY; TUMOR CELL LINE;

CELL LINE, TUMOR; CYSTEINE; HUMANS; IMMUNOCONJUGATES; SELENOCYSTEINE; TRASTUZUMAB;

EID: 84947748635     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00244     Document Type: Article

References (25)

1. Chari, R. V., Miller, M. L., and Widdison, W. C. (2014) Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 53, 3796-3827 10.1002/anie.201307628
2. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29 10.1146/annurev-med-050311-201823
3. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-537 10.1016/j.cbpa.2010.06.170
4. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjugate Chem. 21, 5-13 10.1021/bc9002019
5. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., and Abdiche, Y. et al. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-167 10.1016/j.chembiol.2013.01.010
6. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., and Zabinski, R. F. et al. 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070 10.1158/1078-0432.CCR-04-0789
7. Wang, L., Amphlett, G., Blattler, W. A., Lambert, J. M., and Zhang, W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry Protein Sci. 14, 2436-2446 10.1110/ps.051478705
8. Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., and Saad, O. et al. 2011, Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats Bioconjugate Chem. 22, 1994-2004 10.1021/bc200212a
9. Panowski, S., Bhakta, S., Raab, H., Polakis, P., and Junutula, J. R. (2014) Site-specific antibody drug conjugates for cancer therapy mAbs 6, 34-45 10.4161/mabs.27022
10. Agarwal, P. and Bertozzi, C. R. (2015) Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Bioconjugate Chem. 26, 176-192 10.1021/bc5004982
11. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., and Dennis, M. S. et al. 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932 10.1038/nbt.1480
12. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., and Li, G. et al. 2010, Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16, 4769-4778 10.1158/1078-0432.CCR-10-0987
13. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., and Nicholas, N. D. et al. 2013, A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 24, 1256-1263 10.1021/bc400217g
14. Hofer, T., Thomas, J. D., Burke, T. R., Jr., and Rader, C. (2008) An engineered selenocysteine defines a unique class of antibody derivatives Proc. Natl. Acad. Sci. U. S. A. 105, 12451-12456 10.1073/pnas.0800800105
15. Hofer, T., Skeffington, L. R., Chapman, C. M., and Rader, C. (2009) Molecularly defined antibody conjugation through a selenocysteine interface Biochemistry 48, 12047-12057 10.1021/bi901744t
16. Hatfield, D. L., Tsuji, P. A., Carlson, B. A., and Gladyshev, V. N. (2014) Selenium and selenocysteine: roles in cancer, health, and development Trends Biochem. Sci. 39, 112-120 10.1016/j.tibs.2013.12.007
17. Barok, M., Joensuu, H., and Isola, J. (2014) Trastuzumab emtansine: mechanisms of action and drug resistance Breast Cancer Res. 16, 209 10.1186/bcr3621
18. Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., and Musto, S. et al. 2015, Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments Mol. Cancer Ther. 14, 952-963 10.1158/1535-7163.MCT-14-0862
19. Yu, S. F., Zheng, B., Go, M. A., Lau, J., Spencer, S., Raab, H., Soriano, R., Jhunjhunwala, S., Cohen, R., and Caruso, M. et al. 2015, A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin based ADCs Clin. Cancer Res. 10.1158/1078-0432.CCR-14-2035
20. Patterson, J. T., Asano, S., Li, X., Rader, C., and Barbas, C. F., 3rd (2014) Improving the serum stability of site-specific antibody conjugates with sulfone linkers Bioconjugate Chem. 25, 1402-1407 10.1021/bc500276m
21. Li, X., Yang, J., and Rader, C. (2014) Antibody conjugation via one and two C-terminal selenocysteines Methods 65, 133-138 10.1016/j.ymeth.2013.05.023
22. Dengl, S., Hoffmann, E., Grote, M., Wagner, C., Mundigl, O., Georges, G., Thorey, I., Stubenrauch, K. G., Bujotzek, A., and Josel, H. P. et al. 2015, Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies FASEB J. 29, 1763-1779 10.1096/fj.14-263665
23. Zhang, B., Ge, C., Yao, J., Liu, Y., Xie, H., and Fang, J. (2015) Selective selenol fluorescent probes: design, synthesis, structural determinants, and biological applications J. Am. Chem. Soc. 137, 757-769 10.1021/ja5099676
24. Steinmann, D., Nauser, T., and Koppenol, W. H. (2010) Selenium and sulfur in exchange reactions: a comparative study J. Org. Chem. 75, 6696-6699 10.1021/jo1011569
25. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., and Mai, E. et al. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-189 10.1038/nbt.2108